<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE1D1D4E-03D6-4D45-9048-74BFF08DA68A"><gtr:id>EE1D1D4E-03D6-4D45-9048-74BFF08DA68A</gtr:id><gtr:name>Peptinnovate Limited</gtr:name><gtr:address><gtr:line1>90 HIGH HOLBORN</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>WC1V 6XX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE1D1D4E-03D6-4D45-9048-74BFF08DA68A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>EE1D1D4E-03D6-4D45-9048-74BFF08DA68A</gtr:id><gtr:name>Peptinnovate Limited</gtr:name><gtr:address><gtr:line1>90 HIGH HOLBORN</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>WC1V 6XX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>249989.0</gtr:offerGrant><gtr:projectCost>555655.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9ADDF18D-FFF7-4C43-AA95-7D5B50528625"><gtr:id>9ADDF18D-FFF7-4C43-AA95-7D5B50528625</gtr:id><gtr:firstName>Clare</gtr:firstName><gtr:surname>Burgess</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720539"><gtr:id>2A573774-0727-4557-825D-0C5DB06AD265</gtr:id><gtr:title>Late preclinical development of a treatment for acute inflammatory disease derived from M.tuberculosis bacteria</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720539</gtr:grantReference><gtr:abstractText>Tuberculosis bacteria (mTB) are present in about 2 billion people worldwide; they have
evolved over millennia to remain hidden in the body by producing proteins that modulate the
host's immune system. These proteins have been shown to interact with and reduce the body's
natural inflammatory processes.
Peptinnovate?s innovation
Peptinnovate?s approach is to unlock the anti-inflammatory activity of these proteins and to
develop new medicines for debilitating diseases such as acute organ failure and COPD.
Building on evolution, nature's ingenuity and employing Peptinnovate?s drug discovery and
development skills we have modified these proteins to more drug-like molecules and are
progressing the candidate molecule, PIN201104, to the clinic.
Aims
Following scientific advice and approval from the MHRA and previous SMART support
(720364), this project will enable our drug candidate, PIN201104, to be evaluated in GLP nonclinical
toxicology studies, and manufactured and formulated to GMP standards for acute use
via intravenous dosing. Alongside this we will also carry out further in vivo efficacy studies in
a range of inflammatory disease models to widen the therapeutic utility of the molecule.
Objectives
? To perform MHRA approved GLP toxicology and safety pharmacology studies in the
rat and dog,
? To manufacture and evaluate PIN201104 drug substance and drug product to GMP
standards ready for clinical studies,
? To demonstrate efficacy in a range of animal models of inflammation to extend
PIN201104?s range of clinical indications.
Benefits, outcomes and impacts
The worldwide market for inflammatory disease treatment is substantial (&amp;gt;$70 billion),
however recent safety scares have been attributed to a number of key drugs. Peptinnovate?s
paradigm shift in potential treatment options will have a profound impact on the lives of
millions of patients, reducing the burden on the healthcare providers and helping to build a
sustainable, UK based pharmaceutical company.</gtr:abstractText><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>249989</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720539</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>